Abstract
Background and objectives Obstructive sleep apnea (OSA) is an underdiagnosed respiratory disease with negative metabolic and cardiovascular effects. The current gold standard for diagnosing OSA is in-hospital polysomnography, a time-consuming and costly procedure, often inconvenient for the patient. Recent studies revealed evidence for the potential of breath analysis for the diagnosis of OSA based on a disease-specific metabolic pattern. However, none of these findings were validated in a larger and broader cohort, an essential step for its application in clinics.
Methods In the present study, we validated a panel of breath biomarkers in a cohort of patients with possible OSA (N = 149). These markers were previously identified in our group by secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS).
Results Here, we could confirm significant differences between metabolic patterns in exhaled breath from OSA patients compared to control subjects without OSA as well as the association of breath biomarker levels with disease severity. Our prediction of the diagnosis for the patients from this completely independent validation study using a classification model trained on the data from the previous study resulted in an area under the receiver operating characteristic curve of 0.66, which is comparable to questionnaire-based OSA screenings.
Conclusions Thus, our results suggest that breath analysis by SESI-HRMS could be used to screen for OSA. Its true predictive power should be tested in combination with OSA screening questionnaires.
Clinical trial “Mass Spectral Fingerprinting in Obstructive Sleep Apnoea”, NCT02810158, www.ClinicalTrials.gov
Competing Interest Statement
M. Kohler declares fees from Bayer, Novartis, Roche, Astra Zeneca, Boehringer Ingelheim, Mundipharma, GSK and Philips outside the submitted work. M. Kohler and P. Sinues are co-founders and board members of the Deep Breath Initiative (DBI), a company that provides services in the field of exhaled breath analysis.
Clinical Trial
NCT02810158
Funding Statement
The study was supported by Uniscientia foundation and Schwyzer foundation. Pablo Sinues received funding from Fondation Botnar (Switzerland).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the local ethical committee Kantonale Ethikkommission des Kanton Zuerich (2016-00384). The experiments were conducted in accordance with the Declaration of Helsinki and written informed consent was obtained from all participants before participation.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The original data and code used in this publication are made available in a curated data archive at ETH Zurich (https://www.research-collection.ethz.ch) under the DOI 10.3929/ethz-b-000456155.
https://www.research-collection.ethz.ch/handle/20.500.11850/456155
